Friedrich Laub is a partner in the Intellectual Property practice group who focuses his global practice on biomedical inventions.

He works to develop and implement global intellectual property and patent strategies across a wide variety of technologies, such as biopharmaceuticals, biotechnology, and molecular- and immuno-diagnostics. He has particular experience with biologic drug products (e.g., gene therapy, antibodies, fusion-proteins, cell therapy) and antisense oligonucleotides. He also advises clients on IP transactional matters, such as collaboration, licensing and M&A deals. 

He takes a creative and holistic approach to intellectual property management and protection, and he is particularly excited about implementing artificial intelligence-based technologies in freedom-to-operate assessments and patent preparation processes.

Friedrich’s clients benefit from his doctorate in molecular biology and more than 25 years of combined experience as a scientist in biomedical research, attorney in law firms and in-house counsel in corporations. Particularly his in-house counsel experience provides him with significant business acumen, an understanding of corporate dynamics and the ability to anticipate clients’ needs.

His in-house experience has also provided him with the skills to craft patents that target potential market competitors with great accuracy, are easily enforceable and work in tandem with regulatory requirements often found in the life sciences industry. 

Friedrich is a dual national of the U.S. and Germany and speaks German fluently.